BioXcel Therapeutics announced that it has commenced an underwritten public offering of $60M of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities to be sold in the offering are being sold by the company. The company intends to use the net proceeds of this offering to fund ongoing and planned clinical trials, commercialization and general corporate purposes. BofA Securities and Truist Securities are acting as joint book-running managers for the proposed public offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics Announces Proposed Public Offering
- Biotech Alert: Searches spiking for these stocks today
- BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701
- BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
- BioXcel Therapeutics announces USPTO’s allowance of patent application